These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
246 related articles for article (PubMed ID: 10635614)
21. Strategy to manage the treatment of severe psoriasis: considerations of efficacy, safety and cost. Feldman SR; Garton R; Averett W; Balkrishnan R; Vallee J Expert Opin Pharmacother; 2003 Sep; 4(9):1525-33. PubMed ID: 12943482 [TBL] [Abstract][Full Text] [Related]
22. Therapy of moderate and severe psoriasis. Claes C; Kulp W; Greiner W; von der Schulenburg JM; Werfel T GMS Health Technol Assess; 2006 Apr; 2():Doc07. PubMed ID: 21289958 [TBL] [Abstract][Full Text] [Related]
23. A simple method to predict whether topical agents will interfere with phototherapy. Kornreich C; Zheng ZS; Xue GZ; Prystowsky JH Cutis; 1996 Feb; 57(2):113-8. PubMed ID: 8646856 [TBL] [Abstract][Full Text] [Related]
24. Comparative tolerability of systemic treatments for plaque-type psoriasis. McClure SL; Valentine J; Gordon KB Drug Saf; 2002; 25(13):913-27. PubMed ID: 12381213 [TBL] [Abstract][Full Text] [Related]
25. Systemic treatment for moderate to severe psoriasis: estimates of failure rates and direct medical costs in a north-eastern US managed care plan. Feldman SR; Evans C; Russell MW J Dermatolog Treat; 2005 Feb; 16(1):37-42. PubMed ID: 15897166 [TBL] [Abstract][Full Text] [Related]
26. Treatment of psoriasis. Part 1. Topical therapy and phototherapy. Lebwohl M; Ali S J Am Acad Dermatol; 2001 Oct; 45(4):487-98; quiz 499-502. PubMed ID: 11568737 [TBL] [Abstract][Full Text] [Related]
27. Combination phototherapy of psoriasis with narrow-band UVB irradiation and topical tazarotene gel. Behrens S; Grundmann-Kollmann M; Schiener R; Peter RU; Kerscher M J Am Acad Dermatol; 2000 Mar; 42(3):493-5. PubMed ID: 10688723 [TBL] [Abstract][Full Text] [Related]
28. Advances in Psoriasis. Smith J; Cline A; Feldman SR South Med J; 2017 Jan; 110(1):65-75. PubMed ID: 28052180 [TBL] [Abstract][Full Text] [Related]
31. Novel therapies for psoriasis. Cather J; Menter A Am J Clin Dermatol; 2002; 3(3):159-73. PubMed ID: 11978137 [TBL] [Abstract][Full Text] [Related]
32. Combining biologic therapies with other systemic treatments in psoriasis: evidence-based, best-practice recommendations from the Medical Board of the National Psoriasis Foundation. Armstrong AW; Bagel J; Van Voorhees AS; Robertson AD; Yamauchi PS JAMA Dermatol; 2015 Apr; 151(4):432-8. PubMed ID: 25517130 [TBL] [Abstract][Full Text] [Related]
33. Ultraviolet B Phototherapy for Psoriasis: Review of Practical Guidelines. Mehta D; Lim HW Am J Clin Dermatol; 2016 Apr; 17(2):125-33. PubMed ID: 26872953 [TBL] [Abstract][Full Text] [Related]
34. A comparison of psoralen plus ultraviolet A (PUVA) monotherapy, tacalcitol plus PUVA and tazarotene plus PUVA in patients with chronic plaque-type psoriasis. Tzaneva S; Hönigsmann H; Tanew A; Seeber A Br J Dermatol; 2002 Oct; 147(4):748-53. PubMed ID: 12366423 [TBL] [Abstract][Full Text] [Related]
35. Acitretin for the treatment of psoriasis: an assessment of national trends. Ghasri P; Yentzer BA; Dabade TS; Feldman SR J Drugs Dermatol; 2011 Aug; 10(8):873-7. PubMed ID: 21818508 [TBL] [Abstract][Full Text] [Related]
36. Psoriasis therapy: a current perspective. Lowe NJ West J Med; 1983 Aug; 139(2):184-9. PubMed ID: 6195826 [TBL] [Abstract][Full Text] [Related]
37. Retrospective analysis of the effectiveness and costs of traditional treatments for moderate-to-severe psoriasis: A single-center, Italian study. Carpentieri A; Pacello L; De Marco IM; Loiacono A; Picconi O; Loconsole F J Dermatolog Treat; 2016 Oct; 27(5):399-405. PubMed ID: 26822691 [TBL] [Abstract][Full Text] [Related]
39. Principal determinants of the length of remission of psoriasis vulgaris after topical, NB-UVB, and PUVA therapy: a follow-up study. Coimbra S; Oliveira H; Belo L; Figueiredo A; Rocha-Pereira P; Santos-Silva A Am J Clin Dermatol; 2013 Feb; 14(1):49-53. PubMed ID: 23329079 [TBL] [Abstract][Full Text] [Related]